International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 33-37 , 1 January 2006

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy

  • Barbara Frederick, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO
    • ,
  • Dan Gustafson, Ph.D.

      Affiliations

    • Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, CO
    • ,
  • Cataldo Bianco, M.D.

      Affiliations

    • Dipartimento di Oncologia, dei Trapianti e delle Nuove Technologie in Medicina, Universita di Pisa, Pisa, Italy
    • ,
  • Fortunato Ciardiello, M.D.

      Affiliations

    • Department of Molecular and Clinical Endocrinology, Universita degli Studi di Napoli Federico II, Naples, Italy
    • ,
  • Isaiah Dimery, Ph.D.

      Affiliations

    • AstraZeneca, Wilmington, DE
    • ,
  • David Raben, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO
    • Corresponding Author InformationReprint requests to: David Raben, M.D., Department of Radiation Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, 1665 N. Ursula St., Suite 1032, F796, Aurora, CO 80010-0510. Tel: (720) 848-0116; Fax: (720) 848-0222

Received 22 March 2005 ,Revised 4 May 2005 ,Accepted 6 May 2005.

References 

  1. Wedge SR , Ogilvie DJ , Dukes M , et al.   ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration . Cancer Res . 2002;62:4645–4655
  2. Eskens FA . Angiogenesis inhibitors in clinical development (Where are we now and where are we going?) . Br J Cancer . 2004;90:1–7
  3. Folkman J . Tumor angiogenesis (Therapeutic implications) . N Engl J Med . 1971;285:1182–1186
  4. Ferrara N , Davis-Smyth T . The biology of vascular endothelial growth factor . Endocr Rev . 1997;18:4–25
  5. Abdollahi A , Lipson KE , Han X , et al.   SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro . Cancer Res . 2003;63:3755–3763
  6. Gorski DH , Beckett MA , Jaskowiak NT , et al.   Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation . Cancer Res . 1999;59:3374–3378
  7. Steiner HH , Karcher S , Mueller MM , et al.   Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme (Clinical relevance of radiation-induced increase of VEGF levels) . J Neurooncol . 2004;66:129–138
  8. Koukourakis MI , Giatromanolaki A , Sivridis E , et al.   Squamous cell head and neck cancer (Evidence of angiogenic regeneration during radiotherapy) . Anticancer Res . 2001;21:4301–4309
  9. Fukumura D , Gohongi T , Kadambi A , et al.   Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability . Proc Natl Acad Sci USA . 2001;98:2604–2609
  10. Sonveaux P , Brouet A , Havaux X , et al.   Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway (Implications for tumor radiotherapy) . Cancer Res . 2003;63:1012–1019
  11. Lee CG , Heijn M , di Tomaso E , et al.   Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions . Cancer Res . 2000;60:5565–5570
  12. Geng L , Donnelly E , McMahon G , et al.   Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy . Cancer Res . 2001;61:2413–2419
  13. Ning S , Laird D , Cherrington JM , et al.   The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation . Radiat Res . 2002;157:45–51
  14. Griffin RJ , Williams BW , Wild R , et al.   Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response . Cancer Res . 2002;62:1702–1706
  15. Teicher BA , Holden SA , Ara G , et al.   Influence of an anti-angiogenic treatment on 9L gliosarcoma (oxygenation and response to cytotoxic therapy) . Int J Cancer . 1995;61:732–737
  16. Tong RT , Boucher Y , Kozin SV , et al.   Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors . Cancer Res . 2004;64:3731–3736
  17. Jain RK . Normalization of tumor vasculature (An emerging concept in antiangiogenic therapy) . Science . 2005;307:58–62
  18. Wachsberger P , Burd R , Dicker AP . Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents (Exploring mechanisms of interaction) . Clin Cancer Res . 2003;9:1957–1971
  19. Harari PM . Epidermal growth factor receptor inhibition strategies in oncology . Endocr Relat Cancer . 2004;11:689–708
  20. Park JS , Qiao L , Su ZZ , et al.   Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways . Oncogene . 2001;20:3266–3280
  21. Raben D , Helfrich B , Chan DC , et al.   The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer . Clin Cancer Res . 2005;11:795–805
  22. Milas L , Mason K , Hunter N , et al.   In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody . Clin Cancer Res . 2000;6:701–708
  23. Bianco C , Tortora G , Bianco R , et al.   Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) . Clin Cancer Res . 2002;8:3250–3258
  24. Maddineni SB , Sangar VK , Hendry JH , et al.   Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines . Br J Cancer . 2005;92:125–130
  25. Bonner JA , Giralt J , Harari PM , et al.   Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck (A phase III study of high dose radiation therapy with or without cetuximab) . [Abstract] Proc Am Soc Clin Oncol . 2004;22(Suppl.):5507
  26. Hoang T , Huang S-M , Armstrong E , et al.   Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474 . [Abstract] Proc Am Assoc Cancer Res . 2004;45:955
  27. Williams KJ , Telfer BA , Brave S , et al.   ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy (Schedule-dependent enhancement of antitumor activity) . Clin Cancer Res . 2004;10:8587–8593
  28. Gustafson DL , Merz AL , Zirrolli JA , et al.   Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts . [Abstract] Eur J Cancer Suppl . 2004;2:45–46
  29. Shibuya K , Komaki R , Wu W , et al.   Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non–small-cell lung cancer . [Abstract] Int J Radiat Oncol Biol Phys . 2004;60(Suppl.):S145–S146
  30. Siemann D , Shi W . The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation . [Abstract] Eur J Cancer Suppl . 2004;2:49
  31. Damiano V , Melisi D , Bianco C , et al.   Cooperative anti-tumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma . Clin Cancer Res . 2005;11:5639–5644
  32. Holden SN , Eckhardt SG , Basser R , et al.   Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumors . Ann Oncol . 2005;16:1391–1397
  33. Minami H , Ebi H , Tahara M , et al.   A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors . [Abstract] Proc Am Soc Clin Oncol . 2003;22:194
  34. Zirrolli JA , Bradshaw EL , Long ME , et al.   Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues . J Pharm Biomed Anal . 2005;39:705–711
  35. Ciardiello F , Bianco R , Caputo R , et al.   Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy . Clin Cancer Res . 2004;10:784–793
  36. Siemann DW , Shi W . Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors . Int J Radiat Oncol Biol Phys . 2004;60:1233–1240
  37. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  38. Willett CG , Boucher Y , di Tomaso E , et al.   Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer . Nat Med . 2004;10:145–147

PII: S0360-3016(05)00962-4

doi: 10.1016/j.ijrobp.2005.05.050

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 33-37 , 1 January 2006

Article Tools

* Image Usage & Resolution